medigraphic.com

2007, Número 4

<< Anterior Siguiente >>

Anales de Radiología México 2007; 6 (4)


Gadolinio y fibrosis nefrogénica sistémica

Huicochea CS, Téliz MMA, Barrientos PAH, González AAJ, Vázquez LJ

Idioma: Español
Referencias bibliográficas: 37
Paginas: 321-326
Archivo PDF: 303.41 Kb.


RESUMEN

Introducción: La fibrosis nefrogénica sistémica (FNS), es una enfermedad que se caracteriza por sus hallazgos cutáneos predominantes. En algunos pacientes existe involucro sistémico; Fue descrita por primera vez en 1997.
Metodología: Esta enfermedad se ha asociado con una combinación de factores incluyendo función renal alterada, procesos inflamatorios y la exposición a medios de contraste basados en Gadolinio.
Gadolinio y fibrosis nefrogénica sistémica: El mecanismo por el cual los medios de contraste hechos a base de Gadolinio pueden desencadenar FNS no es del todo bien conocido; sin embargo la fuerte asociación entre el Gadolinio y la FNS limita su uso en pacientes con insuficiencia renal. En esta revisión se presenta la situación actual de la FNS, su asociación con el uso de los medios de contraste que contienen Gadolinio y las recomendaciones propuestas por diferentes organizaciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Grobner T. Gadolinium –a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-8.

  2. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-62.

  3. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation. Radiology 2007; 243: 148-57.

  4. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and NFS: retrospective study of a renal replacement therapy cohort. Radiology 2007; 245(1): 168-75.

  5. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 2007; 188: 586-92.

  6. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic systemic fibrosis. A review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007; 42: 139-45.

  7. Caccetta T, Chan J. Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium. Australas J Dermatol 2008; 49(1): 48-51.

  8. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 2008; 190(3): 736-41.

  9. Public Assessment Report (updated June 26, 2007). [Available at: http://www.esur.org/fileadmin/NSF/Public_Assessment_Report_NSF_Gadolinium_26_June_2007.pdf.] (Accesado: 23/02/2008).

  10. Bongartz G. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? Magn Reson Mater Phy 2007; 20: 57-62.

  11. FDA Alert. Information for healthcare professionals, GBCAs for MRI [WWW document], 2007. URL http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705HCP.pdf. (Accesado: 23/02/2008).

  12. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodyalisis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5: 491-502.

  13. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-01.

  14. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383-93.

  15. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139: 903-6.

  16. Cowper SE. Nephrogenic systemic fibrosis: The nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005; 46: 763-5.

  17. Kurtkoti J, Snow T, Hiremagalur B. Gadolinium and nephrogenic systemic fibrosis: Association or causation. Nephrology 2008; 13(3): 235-41 doi:10.1111/j.1440-1797.2007.00912.x

  18. Cowper SE. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2007. Available at: http://www.icnfdr.org. (Accesado: 23/02/2008).

  19. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-62.

  20. Baron PW, Cantos K, Hillebrand DJ, Hu KQ, Ojogho ON, Nehlsen-Cannarella S, Concepcion W. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003; 25(3): 204-9.

  21. Maloo M, Abt P, Kashyap R, Younan D, Zand M, Orloff M, Jain A, Pentland A, Scott G, Bozorgzadeh A. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006; 6(9): 2212-7.

  22. Swaminathan S, Shah SV. New Insights into Nephrogenic Systemic Fibrosis. J Am Soc Nephrol 2007; 18(10): 2636-43.

  23. Cowper SE. Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol 2003; 15: 785-90.

  24. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35: 238-49.

  25. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004; 30: 569-77.

  26. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Report of a new case with literature review. Am J Kidney Dis 2005; 46: 754-9.

  27. Gremmels JM, Kirk GA. Two patients with abnormal skeletal muscle uptake of Tc-99m hydroxymethylene diphosphonate following liver transplant: Nephrogenic fibrosing dermopathy and graft vs host disease. Clin Nucl Med 2004; 29: 694-7.

  28. Linfert DR, Schell JO, Fine DM. Treatment of Nephrogenic Systemic Fibrosis: Limited Options but Hope for the Future. Semin Dial 2008; doi: 10.1111/j.1525-139X.2007.00407.x.

  29. Kuo PH, Kanal E, Abu-Alfa AK, et al. Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis Radiology 2007; 242: 647-9.

  30. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissues of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56(4): 710-2.

  31. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56(1): 27-30.

  32. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008; 158(2): 273-80.

  33. Thakral C, Abraham JL. Biological: Fulllength Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of Gadolinium deposits in skin. J Electron Microsc (Tokyo) 2007; 56(5): 181-7.

  34. Houck CM, Pristave RJ, Kannensohn KJ. Nephrogenic Systemic Fibrosis and Gadolinium- Based Contrast: Medico-Legal Implications. Semin Dial 2008; doi: 10.1111/j.1525-139X.2007.00404.x.

  35. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1996; 6: 162-6.

  36. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 2007; 179-84.

  37. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006; 16: 2619-21.




2020     |     www.medigraphic.com